A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

开始日期2025-06-01

申办/合作机构

Pharmazz, Inc.

CTRI/2024/07/070459

/ Not yet recruiting临床4期

Safety and efficacy of sovateltide in acute cerebral ischemic stroke patients at a tertiary care centre-a double blinded block randomised placebo controlled study - NIL

开始日期2024-07-22

申办/合作机构

Pondicherry Institute of Medical Sciences

NCT05955326

/ Recruiting临床4期

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.

开始日期2024-01-08

申办/合作机构

Pharmazz, Inc.

100 项与 Sovateltide 相关的临床结果

登录后查看更多信息

100 项与 Sovateltide 相关的转化医学

登录后查看更多信息

100 项与 Sovateltide 相关的专利（医药）

登录后查看更多信息

388

项与 Sovateltide 相关的文献（医药）

2025-03-01·EXPERIMENTAL NEUROLOGY

Microglial cell proliferation is regulated, in part, by reactive astrocyte ETBR signaling after ischemic stroke

Article

作者: Torsney, Emily E ; LeComte, Matthew D ; Del Rio-Guerra, Roxana ; Poynter, Matthew E ; Spees, Jeffrey L ; McInnis, John J ; Reed, Leah F

Reciprocal communication between reactive astrocytes and microglial cells provides local, coordinated control over critical processes such as neuroinflammation, neuroprotection, and scar formation after CNS injury, but is poorly understood. The vasoactive peptide hormone endothelin (ET) is released and/or secreted by endothelial cells, microglial cells and astrocytes early after ischemic stroke and other forms of brain injury. To better understand glial cell communication after stroke, we sought to identify paracrine effectors produced and secreted downstream of astroglial endothelin receptor B (ETB_R) signaling. Using a genetic loss-of-function screen, we identified angiopoietin-2 (Ang-2) as a factor produced by reactive astrocytes in response to ET. In experiments with primary adult astrocytes stimulated by IRL1620, a specific ETB_R agonist, we found that ERK1/2 and NFkB mediated the effects of ET on Ang-2 production. To determine astroglial Ang-2 levels in vivo, reactive astrocytes expressing the high affinity glutamate transporter (GLAST, EAAT1) were isolated by magnetic-activated cell sorting 3 days after stroke. Astrocytes obtained from the ipsilateral hemisphere expressed significantly more Ang-2 compared with astrocytes isolated from the contralateral hemisphere, or from cortices of sham-operated (control) mice. Notably, analysis of microglia sorted from CX3CR1-eGFP mice demonstrated increased cell surface expression of Tie-2, the Ang-2 receptor, on cells obtained from ipsilateral versus contralateral tissue. Addition of recombinant Ang-2 to astrocyte-conditioned medium significantly increased the number of SIM-A9 murine microglial cells cultured under hypoxic conditions (1 % oxygen for 48 h). In transgenic GFAP-CreER™-EDNRB-^fl/fl mice with stroke, conditional knockout of astroglial ETB_R significantly decreased the number of proliferating cells in the peri-infarct area with a microglial phenotype (Ki67⁺/CD11b⁺). Our results indicate that Ang-2, and possibly other paracrine effectors functioning downstream of astroglial ETB_R signaling, are important mediators of microglial cell dynamics after stroke.

2024-12-01·DRUGS

Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

Article

作者: Siddiqui, Mohd Shafat Imam ; Adwani, Sikandar Gokuldas ; Khurana, Dheeraj ; Sidhu, Gursaran Kaur ; Joshi, Deepika ; Karadan, Ummer ; Ramakrishnan, T C R ; Aralikatte, Saroja ; Rai, Hari Prakash ; Sharma, Mridul ; Sundarachary, Nagarjunakonda Venkata ; Vijaya, Pamidimukkala ; Jain, Dinesh ; Anand, Sidharth Shankar ; Vibha, Deepti ; Agrawal, Nilesh Radheshyam ; Gulati, Anil ; Pandian, Jeyaraj Durai ; Sardana, Vijay

BACKGROUND AND OBJECTIVES:

Sovateltide (Tycamzzi™), an endothelin-B (ET-B) receptor agonist, increases cerebral blood flow, has anti-apoptotic activity, and promotes neural repair following cerebral ischaemic stroke. The objectives of this study were to evaluate the efficacy and safety of sovateltide in adult participants with acute cerebral ischaemic stroke.

METHODS:

This was a randomised, double-blind, placebo-controlled, multicentre, Phase III clinical trial of sovateltide in participants with cerebral ischaemic stroke receiving standard of care (SOC) in India. Patients aged 18-78 years presenting up to 24 h after the onset of symptoms with radiologic confirmation of ischaemic stroke and a National Institutes of Health Stroke Scale score (NIHSS) of ≥ 6 were enrolled. Patients with recurrent stroke, receiving endovascular therapy, or with intracranial haemorrhage were excluded. The study drug (saline or sovateltide [0.3 µg/kg] was administered intravenously in three doses at 3 ± 1 h intervals on Days 1, 3, and 6, and follow-up was 90 days). The Multivariate Imputation by Chained Equations (MICE) was used to impute the missing assessments on the endpoints. An unpaired t-test, two-way analysis of variance with Tukey's multiple comparison test, and the Chi-square test were used for the statistical analysis. The objective was to determine at Day 90 (1) the number of patients with a modified Rankin Scale score (mRS) 0-2, and (2) the number of patients with an NIHSS 0-5 at 90 days.

RESULTS:

Patients were randomised with 80 patients in the sovateltide and 78 in the control group. Patients received the investigational drug at about 18 h of stroke onset in both control and sovateltide groups. The median NIHSS at randomisation was 10.00 (95% CI 9.99-11.65) in the control group and 9.00 (95% CI 9.11-10.46) in the sovateltide group. Seventy patients completed the 90-day follow-up in the control group and 67 in the sovateltide group. The proportion of intention-to-treat (ITT) patients with mRS 0-2 score at Day 90 post-randomisation was 22.67% higher (odds ratio [OR] 2.75, 95% CI 1.37-5.57); similarly, the proportion of patients with NIHSS score of 0-5 at Day 90 was 17.05% more (OR 2.67, 95% CI 1.27-5.90) in the sovateltide group than in the control group. An improvement of ≥ 2 points on the mRS was observed in 51.28% and 72.50% of patients in the control and sovateltide groups, respectively (OR 2.50, 95% CI 1.29-4.81). Seven of 78 patients (8.97%) in the control group and 7 of 80 (8.75%) in the sovateltide group developed intracranial haemorrhage (ICH). The adverse events were not related to sovateltide.

CONCLUSIONS:

The sovateltide group had a greater number of cerebral ischaemic stroke patients with lower mRS and NIHSS scores at 90 days post-treatment than the control group. This trial supported the regulatory approval of sovateltide in India, but a multinational RESPECT-ET_B trial will be conducted for US approval.

TRIAL REGISTRATION:

Clinical Trials Registry, India (CTRI/2019/09/021373) and the United States National Library of Medicine, ClinicalTrials.gov (NCT04047563).

2024-10-01·Neurocritical Care

The Effects of IRL-1620 in Post-ischemic Brain Injury: A Systematic Review and Meta-analysis of Experimental Studies

Review

作者: Xanthos, Theodoros ; Pouliakis, Abraham ; Iacovidou, Nikoletta ; Moustakas, Dimitris ; Mani, Iliana

BACKGROUND:

Sovateltide (IRL-1620), an endothelin B receptor agonist, has previously demonstrated neuroprotective and neuroregenerative effects in animal models of acute ischemic stroke. Recently, clinical trials indicated that it could also be effective in humans with stroke. Here, we systematically investigate whether IRL-1620 may be used for the treatment of ischemia-induced brain injury.

METHODS:

A systematic review was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. MEDLINE (PubMed) and Scopus databases were searched for eligible studies up to December 2022. The databases ClinicalTrials.gov and Pharmazz Inc. were screened for unpublished or ongoing trials. Only studies in English were evaluated for eligibility. Meta-analysis of the included studies was also conducted.

RESULTS:

Finally, seven studies were included in the review, all in animal rat models because of scarcity of clinical trials. Six studies, all in middle cerebral artery occlusion (MCAO) models, were selected for meta-analysis. In the two studies assessing mortality, no deaths were reported in the IRL-1620 group 24 h after MCAO, whereas the vehicle group had almost a five times higher mortality risk (risk ratio 5.3, 95% confidence interval 0.7-40.1, I² = 0%). In all five studies evaluating outcome on day 7 after MCAO, IRL-1620 was associated with statistically significantly lower neurological deficit and improved motor performance compared with the vehicle. Infract volume, differentiation potential of neuronal progenitor cells, and mitochondrial fate also improved with IRL-1620 administration.

CONCLUSIONS:

According to the above, in animal MCAO models, IRL-1620 enhanced neurogenesis and neuroprotection and improved outcome. Future studies are needed to expand our understanding of its effects in human study participants with acute ischemic stroke as well as in other common causes of cerebral ischemia including cardiac arrest.

项与 Sovateltide 相关的新闻（医药）

2025-05-26

·echemi

Sun Pharma Amplifies Investment in Pharmazz to $25 Million, Elevating Stake to 22.7%

In a decisive move to bolster its presence in the biopharmaceutical sector, Sun Pharmaceutical Industries Ltd has announced an increased investment in U.S.-based Pharmazz Inc., raising its total commitment to $25 million and expanding its ownership stake to 22.7%. This strategic investment, structured in multiple tranches, is set to be completed by November 30, 2025. The initial tranche includes $10 million, along with the remaining $7.5 million from a prior SAFE (Simple Agreement for Future Equity) arrangement, to be invested by May 31, 2025. A subsequent $15 million tranche is scheduled for investment by November 30, 2025, or another mutually agreed date. Pharmazz is at the forefront of developing innovative treatments for critical care, with two leading drug candidates: Sovateltide, aimed at treating acute cerebral ischemic stroke, and Centhaquine, designed for hypovolemic shock. Both drugs have received approval in India and are marketed under the brand names Tyvalzi and Lyfaquin, respectively. These therapies are currently undergoing development for the U.S. and other international markets. With this enhanced investment, Sun Pharma secures an option to negotiate licensing rights for Sovateltide in certain developed markets, expanding upon its existing exclusive rights in select emerging markets. This move underscores Sun Pharma’s commitment to advancing its portfolio in critical care therapeutics and strengthening its global footprint in the pharmaceutical industry.

引进/卖出上市批准

2025-05-24

·ETPharma

Sun Pharma to invest $25 mn in Pharmazz Inc; raises stake to 22.7 pc

New Delhi: Sun Pharmaceutical Industries Ltd on Friday said it has entered into an agreement with US-based Pharmazz Inc to invest up to USD 25 million, resulting in increasing its stake in the company to 22.7 per cent. The investment triggers conversion of earlier investment through SAFE (simple agreement for future equity) resulting in aggregate stake of up to 22.7 per cent in Pharmazz on a fully diluted basis, the company said in a regulatory filing. The first tranche of USD 10 million, along with the balance of USD 7.5 million out of SAFE tranche 2 investment, will be invested on or before May 31, 2025. The second tranche of USD 15 million will be invested on or before November 30, 2025 or such other mutually agreed date, it added. Pharmazz Inc is a biopharmaceutical company , developing two leading drug candidates , Sovateltide for treatment of acute cerebral ischemic stroke and Centhaquine for treatment of hypovolemic shock. Both products are approved in India and marketed through partners under brands Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine), and are being developed for USA and other markets, it added. Subsequent to the investment, Sun Pharma will receive an option to negotiate licensing of Sovateltide for marketing and distribution in certain developed market countries. The company has already received exclusive right to licence Sovateltide for marketing and distribution in certain emerging market countries, it added.

引进/卖出上市批准

2024-08-26

·医药观澜

10家创新药公司完成新一轮融资，1家来自中国

▎药明康德内容团队报道根据即刻药数数据库，上周（8月19日~8月25日）全球生物制药领域至少10家致力于创新药研发的公司宣布完成新一轮融资，其中包括1家中国公司。这些获得融资的新锐主要致力于开发小分子药物、RNA疗法、线粒体疗法、癌症免疫疗法等，涉及肾病、肥胖和代谢，心血管以及癌症等治疗领域。 Borealis Biosciences 轮次：A轮金额：1.5亿美元 8月22日，Borealis Biosciences宣布走出隐匿模式并获得创始投资者Versant Ventures和诺华（Novartis）合计1.5亿美元的A轮融资。该公司也与诺华达成战略研究合作，共同开发用于治疗肾脏疾病的RNA疗法。 Borealis旨在通过开发RNA疗法促进科学和转化上的突破，以满足肾病患者的主要未满足需求。该公司的目标包括更好地了解患者分层、遗传学定义的治疗靶标，并致力将治疗有效载荷递送到特定肾细胞类型，以及推进RNA化学的进展。此次诺华参与了Borealis的A轮融资，并承诺提供高达1亿美元的前期和短期研究资金。作为协议的一部分，诺华将有权从Borealis收购两个未来的潜在开发项目，Borealis则有资格在达到临床和监管等里程碑后获得总额达7.5亿美元款项。 Ambrosia Biosciences 轮次：A轮金额：1600万美元 8月21日，Ambrosia Biosciences宣布成功完成A轮融资。本次融资总额为1600万美元，由BVF Partners和Boulder Ventures领投。Ambrosia将利用这笔融资扩大其药物发现项目和实验室运营。 Ambrosia Biosciences专注于发现和开发针对GLP-1受体及其他B类G蛋白偶联受体的全新口服小分子疗法。该公司的研发团队来自原Array BioPharma的药物化学团队。在Array BioPharma被辉瑞收购后，这一团队再度启程，在Ambrosia公司将利用在小分子药物发现方面的专长，开发治疗肥胖症和代谢疾病的药物。 Retension Pharmaceuticals 轮次：A轮金额：1040万美元 8月21日，Retension Pharmaceuticals宣布完成A轮1040万美元融资。Retension是一家临床阶段生物医药公司，专注于开发针对高血压和心血管疾病的创新疗法。该公司的主要候选药物RTN-001是在赛诺菲的全球独家许可下开发，为一款第二代PDE5抑制剂。与早期用于勃起功能障碍的PDE5抑制剂不同，该产品被设计优先分布于心血管组织，从而有望克服第一代PDE5抑制剂在高血压领域的局限性。在此前包括265多名受试者的多项临床试验中，该药耐受性良好，显示出对难治性高血压患者的疗效。根据新闻稿，本轮融资将用于启动RTN-001的一项2期临床研究，针对服用两种或两种以上抗高血压药物仍不受控制的高血压患者。 Pharmazz 轮次：战略投资金额：1500万美元 8月21日，Pharmazz公司宣布和Sun Pharma签署一项协议，Sun Pharma将向Pharmazz投资约1500万美元，支持其完成sovateltide治疗急性脑缺血患者的关键3期研究。同时双方将扩大此前签署的许可协议，Sun Pharma将拥有sovateltide在印度以及其他新兴国家的商业化权利。Sovateltide是一种高选择性内皮素B受体激动剂，可增加血流量，显示抗凋亡活性，保护神经线粒体，促进神经血管重塑。 Pharmazz公司专注于发现、收购、开发和商业化针对重症监护医学的治疗方法，产品类型包括肽和其他小分子药物。该公司正在开发三种针对多种重症监护适应症的新型药品，主要产品centhaquine用于治疗低血容量性休克，第二种化合物Sovateltide用于治疗脑缺血性中风、阿尔茨海默病和其他神经退行性疾病。第三种化合物正在开发中，用于治疗糖尿病酮症酸中毒和消除阿片类药物耐受。 Pathalys Pharma 轮次：B轮金额：1.05亿美元 8月20日，专注于肾病疗法研发的Pathalys Pharma宣布完成1.05亿美元的B轮融资，用于完成两项正在进行的临床试验，向美国FDA申报NDA以及加快批准前的商业化准备。该轮超额融资由TCGX牵头，其他投资者也加入其中，包括JP Morgan Life Sciences Private Capital、Samsara BioCapital、Marshall Wace、KB Investment、JPS Growth Investment Limited Partnership，以及得到了创始投资方Catalys Pacific和DaVita Venture Group的支持。 Pathalys专注的重点领域之一是改进继发性甲状旁腺功能亢进症（SHPT）的治疗。该公司在研疗法upacicalcet是一种新型拟钙剂（calcimimetic）。拟钙剂是一种通过激活钙敏感受体来模仿钙在组织上作用的药物，常用于治疗继发性SHPT。Upacicalcet可在透析结束时通过预填充注射器进行静脉注射。研究表明，它能有效降低甲状旁腺激素水平，并且可能为患者提供更好的耐受性。目前在接受透析的终末期肾病患者中进行的关键性3期临床试验项目已经完成首批患者入组。 GondolaBio 轮次：未知轮金额：3亿美元日前，BridgeBio Pharma公司披露，在投资者的支持下成立了一家名为GondolaBio的新公司，并将针对红细胞生成性原卟啉症、α-1抗胰蛋白酶缺乏症和结节性硬化症的早期临床和临床前项目转移到GondolaBio继续开发。此次GondolaBio的投资者包括Viking Global Investors LP、Patient Square Capital、红杉资本（Sequoia Capital）、Frazier Life Sciences、Cormorant Asset Management、Aisling Capital等机构。这些投资者承诺提供3亿美元的分期融资。同源康医药轮次：IPO 金额：5.06亿港元 8月20日，同源康医药正式在港交所上市，募资约5.06亿港元，约70%将用于核心产品的研究、开发及商业化，约20%将用于其他候选产品研发，约3%将用于潜在战略收购或合作机会。同源康医药致力于开发差异化癌症靶向疗法，以满足亟待满足的医疗需求，尤其是肺癌领域。该公司已建立由11款候选药物组成的管线，包括处于3期关键临床阶段的核心产品TY-9591（第三代EGFR-TKI）、其他6款临床阶段产品，以及4款临床前或早期开发阶段产品。 Vandria SA 轮次：A轮融资金额：3070万美元 8月21日，开发线粒体疗法的Vandria SA宣布完成A轮融资的第二次融资，使其总融资金额达到3070万美元（2830万瑞士法郎）。此次Hevolution Foundation和Dolby Family Ventures加入成为投资方，原创始风险投资公司为ND Capital。 Vandria正在开发一种新靶点小分子诱导剂，可诱导线粒体吞噬（选择性去除和替换受损线粒体）和抗炎作用，有望治疗与年龄相关的慢性疾病。其主要候选者VNA-318在临床前研究中被证明可显著改善记忆和学习。VNA-318在阿尔茨海默病和帕金森病模型中具有强疾病调节作用。而且毒性研究表明其具有广泛的安全窗口。除了VNA-318，Vandria还拥有其他促有丝分裂的小分子管线，以解决肌肉、肺和肝脏疾病中未满足的医疗需求。 PhotonPharma 轮次：种子轮金额：250万美元 8月21日，PhotonPharma宣布完成250万美元的种子轮融资。这笔资金将支持Innocell™的1期临床试验，这是一种治疗晚期癌症的新疗法。该公司成立于2018年，致力于开创新型药物输送系统和靶向治疗，旨在改善癌症治疗。2024年2月，PhotonPharma获得美国FDA的批准开始进行Innocell™的临床开发。临床1期试验预计将于2024年第四季度招募首位患者。 Talus Bioscience 轮次：种子+轮金额：1120万美元 8月20日，Talus Bioscience宣布获得1120万美元的种子+轮融资，由Two Bear Capital领投，WRF Capital、NFX、YC Continuity Fund、Funders Club VC和BoxOne Ventures参投。融资资金将用于推进其在研治疗项目，包括短距离驱动癌症和一种与前列腺有关的非药物转录因子等。 Talus Bio创立于2020年，专注于转录因子调节相关疾病的治疗研发。转录因子通过与DNA结合来协调基因开关进而调节蛋白表达。当它们出现问题时，通常会导致癌症和其他疾病过程。该公司专有发现平台MARMOT（转录因子正常调节的多重检测）集成了人工智能、下一代蛋白质组学、合成化学和计算生物学来设计和研究药物、蛋白质和基因组学。希望在投资市场的助力下，更多前沿技术和创新疗法可以早日造福病患。参考资料： [1]各公司官网和公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

并购临床2期免疫疗法信使RNA寡核苷酸

100 项与 Sovateltide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06138

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性缺血性卒中	印度	Pharmazz, Inc.	2023-05-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	印度	Pharmazz, Inc.	2022-08-23
脑梗塞	临床3期	印度	Pharmazz, Inc.	2019-11-10
实体瘤	临床3期	美国	Pharmazz, Inc.	2016-12-25
新生儿窒息	临床2期	印度	Pharmazz, Inc.	2023-09-06
缺氧缺血性脑病	临床2期	印度	Pharmazz, Inc.	2023-09-06
新生儿脑病	临床2期	印度	Pharmazz, Inc.	2023-09-06
窒息	临床2期	美国	Pharmazz, Inc.	2022-08-23
窒息	临床2期	印度	Pharmazz, Inc.	2022-08-23
急性脊髓损伤	临床2期	印度	Pharmazz, Inc.	2019-01-10
非小细胞肺癌	临床2期	美国	Spectrum Pharmaceuticals, Inc.	2013-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


sovateltide (ISC2025)	N/A	脑卒中	-	Sovateltide	選憲醖選艱糧膚壓壓衊(廠艱製憲餘積糧鬱範膚) = 鑰衊鬱鑰蓋窪選鬱蓋淵鹹鑰鏇簾願餘網夢鹽襯 (齋憲選鏇衊憲願衊繭鏇 ) 更多	积极	2025-01-30
				Saline	選憲醖選艱糧膚壓壓衊(廠艱製憲餘積糧鬱範膚) = 襯憲獵鬱構製餘簾範顧鹹鑰鏇簾願餘網夢鹽襯 (齋憲選鏇衊憲願衊繭鏇 ) 更多
NCT04047563 (CTRI/2019/09/021373, Pubmed \| Drugs) 人工标引	临床3期	急性缺血性卒中	158	Sovateltide	鹹鹹範壓艱範顧蓋夢窪(艱夢襯鑰襯鏇廠獵糧鬱) = 壓糧壓膚願獵範餘遞積獵鹽網製鏇鹽顧餘築廠 (顧餘艱鏇廠獵衊夢齋醖 ) 更多	积极	2024-11-15
				Control (Placebo)	淵餘遞艱簾顧夢襯簾齋(鏇衊齋齋構遞夢餘遞淵) = 網獵壓艱糧襯獵遞製襯繭夢醖網顧窪繭襯鹹願 (構網遞繭築鹽夢顧構顧 ) 更多
NCT04047563 (GlobeNewswire) 人工标引	临床3期	急性缺血性卒中	158	Sovateltide	艱鬱鏇顧艱鹽繭觸選簾(獵襯繭積簾觸壓鏇壓艱) = 築簾憲淵鹽鑰鑰獵製顧網繭衊繭製醖鑰廠範鬱 (膚繭鏇齋鑰願蓋廠積齋 ) 更多	积极	2022-10-31
				Placebo	艱鬱鏇顧艱鹽繭觸選簾(獵襯繭積簾觸壓鏇壓艱) = 鏇選膚選齋鹹鑰築鹹顧網繭衊繭製醖鑰廠範鬱 (膚繭鏇齋鑰願蓋廠積齋 ) 更多
NCT04047563 (Biospace) 人工标引	临床3期	急性缺血性卒中	158	standard of care+Sovateltide	醖顧夢廠窪糧鹽鹹願構(鹹鹹鏇鬱顧願繭鹽觸鬱) = improvement of ≥6 points on NIHSS 蓋觸壓壓願壓鏇鑰壓艱 (艱觸衊範廠餘網憲夢網 ) 更多	积极	2022-05-25
				standard of care+Placebo
NCT04052737 (PRNewswire) 人工标引	临床2期	阿尔茨海默症	62	sovateltide	壓選艱繭齋願壓餘鬱窪(網餘餘醖壓醖夢積壓壓) = 鹹繭齋壓範願選膚積艱構餘膚糧淵餘觸鹽淵製 (夢窪願衊鏇鹹鑰製選壓, 0.955) 更多	积极	2021-06-10
				Placebo	壓選艱繭齋願壓餘鬱窪(網餘餘醖壓醖夢積壓壓) = 餘簾簾簾鏇衊選餘獵淵構餘膚糧淵餘觸鹽淵製 (夢窪願衊鏇鹹鑰製選壓, 0.920) 更多
NCT04046484 (Pubmed \| CNS Drugs) 人工标引	临床2期	缺血性卒中	36	Sovateltide	鬱繭糧範鹽鏇鏇繭網遞(壓襯鑰鑰築繭窪齋膚膚) = 鑰蓋艱衊憲夢襯選鏇鏇餘網夢醖築蓋顧膚憲製 (鏇顧鹽願衊夢夢觸顧鏇 ) 更多	积极	2021-01-01
				Placebo	鬱繭糧範鹽鏇鏇繭網遞(壓襯鑰鑰築繭窪齋膚膚) = 選積鬱衊鑰鬱鬱鹽餘簾餘網夢醖築蓋顧膚憲製 (鏇顧鹽願衊夢夢觸顧鏇 ) 更多
AAIC2018	N/A	阿尔茨海默症	-	IRL-1620	糧衊鬱夢鹽製壓淵艱鬱(艱範廠築積鬱鹽艱艱顧) = 構鬱醖網網膚鬱鏇遞衊積壓蓋廠簾窪襯醖齋築 (壓範鏇觸遞夢積製範獵 ) 更多	-	2018-07-01
				Vehicle	糧衊鬱夢鹽製壓淵艱鬱(艱範廠築積鬱鹽艱艱顧) = 願鬱淵衊製廠獵壓餘繭積壓蓋廠簾窪襯醖齋築 (壓範鏇觸遞夢積製範獵 ) 更多
NCT05691244 (Pubmed \| Brain Res)	临床3期	脑缺血	-	IRL-1620	選鹽鏇遞淵糧顧鬱蓋鏇(顧糧鹹鏇衊夢繭鏇遞鑰) = 夢蓋製積餘鬱鹹顧獵範鹹選淵網積壓獵網選獵 (製積衊襯鏇願蓋製夢鹽 )	-	2012-06-29
				Vehicle	選鹽鏇遞淵糧顧鬱蓋鏇(顧糧鹹鏇衊夢繭鏇遞鑰) = 夢蓋鑰襯蓋糧廠鹽夢願鹹選淵網積壓獵網選獵 (製積衊襯鏇願蓋製夢鹽 )
NCT05691244 (Pubmed \| Brain Res)	临床3期	大脑中动脉梗塞	-	IRL-1620	鹹選夢廠憲襯鑰網艱齋(構顧糧積範淵壓遞獵艱) = 網顧襯願獵鹹遞齋積繭壓窪製蓋醖獵膚鑰網選 (築艱鏇顧餘繭憲鹹積網 )	-	2011-10-28
				BQ788	鹹選夢廠憲襯鑰網艱齋(構顧糧積範淵壓遞獵艱) = 窪壓積鹽選繭積築糧廠壓窪製蓋醖獵膚鑰網選 (築艱鏇顧餘繭憲鹹積網 )